CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. SPCX
2. CRNX
3. VRTX
4. WMT
5. LMT
6. RXST
7. SPGI
8. RIVN
9. SPY
10. BFH

Go back to CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results

CRISPR Therapeutics (CRSP) Misses Q4 EPS by 14c; Provides Business Update

February 25, 2019 8:14 AM EST

CRISPR Therapeutics (NASDAQ: CRSP) reported Q4 EPS of ($0.92), $0.14 worse than the analyst estimate of ($0.78). Revenue for the quarter came in at $115 thousand versus the consensus estimate of $2.64 million.

Fourth Quarter and Full Year 2018 Financial Results

Cash Position: Cash and cash equivalents as of December 31, 2018 were $456.6 million, compared to $239.8 million as of December 31, 2017, an increase of $216.8 million, which was primarily driven by the net proceeds of $307.1 million from the sale of shares in follow-on financing rounds executed in January and September of 2018, offset by the Companys use of $96.2 million for operating activities.... More